Aura Biosciences
First pharmacological treatment for ocular melanoma
Aura BioSciences is using its proprietary VDC (virus-like particle-drug conjugates) platform to develop products to treat high unmet needs in ocular and urologic cancers.
Aura’s clinical pipeline includes AU-011, its most advanced product, which is poised to begin registrational studies in primary choroidal melanoma and which is also in Phase I studies in non-invasive muscle bladder cancer.
CEO Elisabet de los Pinos
Advent Contact Raj Parekh
Advent invested in the Series B in 2015.
Publicly Listed
Aura Biosciences Reports Third Quarter 2024 Financial Results and Business Highlights
Press Release. Positive Phase 2 End of Study Data with Bel-sar in Early-Stage Choroidal Melanoma; Ongoing Phase 3 CoMpass Trial Recently Received Authorization to Start Enrolling Patients in Europe Multiple…
Read More
Multiple Clinical Complete Responses Demonstrated Following Single Low Dose Administration of Bel-sar in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) in Ongoing Phase 1 Trial
Press Release. Multiple Clinical Complete Responses Demonstrated Following Single Low Dose Administration of Bel-sar in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) in Ongoing Phase 1 Trial October 17, 2024…
Read More
Aura Biosciences Reports Positive Phase 2 End of Study Results Evaluating Bel-sar as a First-Line Treatment for Early-Stage Choroidal Melanoma
Press Release. Aura Biosciences Reports Positive Phase 2 End of Study Results Evaluating Bel-sar as a First-Line Treatment for Early-Stage Choroidal Melanoma Bel-sar Demonstrated 80% Tumor Control Rate, 90%…
Read More
Aura Biosciences Announces First Patient Dosed in Global Phase 3 CoMpass Trial
Press Release. Aura Biosciences Announces First Patient Dosed in Global Phase 3 CoMpass Trial Evaluating the Safety and Efficacy of Belzupacap Sarotalocan (Bel-sar) for First-Line Treatment of Early-Stage Choroidal…
Read More
Aura Biosciences Receives FDA Agreement for CoMpass Phase 3 Clinical Trial
Press Release. Aura Biosciences Receives FDA Agreement Under Special Protocol Assessment (SPA) for CoMpass Phase 3 Clinical Trial of Belzupacap Sarotalocan (Bel-sar) in Early-stage Choroidal Melanoma November 6, 2023…
Read More
Eloxx Pharmaceuticals Announces Submission of Investigational New Drug (IND) Application for ZKN-013
Press Release. ZKN-013 in development for treatment of recessive dystrophic epidermolysis bullosa (RDEB) and junctional epidermolysis bullosa (JEB) Additional IND filing for ZKN-013 for treatment of familial adenomatous polyposis…
Read More
Aura Biosciences Announces Positive Interim Phase 2 Safety and Efficacy Data of Belzupacap Sarotalocan (Bel-sar) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma with Suprachoroidal Administration
Press Release. Aura Biosciences Announces Positive Interim Phase 2 Safety and Efficacy Data of Belzupacap Sarotalocan (Bel-sar) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma with Suprachoroidal…
Read More
Aura Biosciences Announces Pricing of Public Offering of Common Stock
Press Release. BOSTON--(BUSINESS WIRE)-- Aura Biosciences, Inc. (“Aura”) (Nasdaq: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced…
Read More
Aura Biosciences Reports Third Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights
Press Release. Announced the Global Phase 3 Trial Design with Suprachoroidal Route of Administration of Belzupacap Sarotalocan in Early-Stage Choroidal Melanoma First Patient Dosed in the Phase 1 Study Evaluating…
Read More
Aura Announces Global Phase 3 Trial Design with Suprachoroidal Route of Administration Based on Positive Phase 2 Interim Data of Belzupacap Sarotalocan in Early-Stage Choroidal Melanoma
Press Release. BOSTON, MA – November 10, 2022 – Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for…
Read More
Aura Biosciences Announces Interim Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (AU-011) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma Presented at AAO 2022
Press Release. BOSTON - (BUSINESS WIRE) - Oct. 3, 2022 - Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC)…
Read More
Aura Biosciences Announces First Patient Dosed in Phase 1 Study Evaluating Belzupacap Sarotalocan (AU-011) for the Treatment of Non-Muscle Invasive Bladder Cancer
Press Release. BOSTON - (BUSINESS WIRE) 28.09.2022 - Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple…
Read More
Aura Biosciences Receives FDA Fast Track Designation for Belzupacap Sarotalocan (AU-011) for the Treatment of Non-Muscle Invasive Bladder Cancer
Press Release. CAMBRIDGE, Mass. -- (BUSINESS WIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple…
Read More
Aura Biosciences Announces Publication of Preclinical Data of the Combination of VDCs with Immune Checkpoint Inhibitors at the 2022 ASCO Annual Meeting
Press Release. CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today…
Read More
Aura Biosciences Presents Preclinical Data Highlighting AU-011’s Anti-Tumor Activity in Choroidal Metastasis, an Additional Ocular Oncology Indication at the 2022 ARVO Annual Meeting
Press Release. Preclinical studies support further development of AU-011 for choroidal metastasis CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of…
Read More
Aura Biosciences to Present Preclinical Data Highlighting AU 011’s Potential to Target a Broad Number of Tumor Types at the 2022 AACR Annual Meeting
Press Release. CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today…
Read More
Aura Biosciences Presents Final Phase 1b/2 Data for its first Virus-Like Drug Conjugate, AU-011, in Patients with Choroidal Melanoma at the American Academy of Ophthalmology
Press Release. Aura Biosciences Presents Final Phase 1b/2 Data for its first Virus-Like Drug Conjugate, AU-011, in Patients with Choroidal Melanoma at the American Academy of Ophthalmology 2021 Annual…
Read More
Aura Biosciences Announces Pricing of Initial Public Offering
Press Release. October 28, 2021 09:39 PM Eastern Daylight Time CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aura Biosciences, Inc. (“Aura”), a clinical-stage oncology company developing a novel class of virus-like drug conjugate therapies…
Read More
Aura Biosciences Presents Interim Phase 2 Safety Data Evaluating Suprachoroidal Administration of AU-011 in Patients with Choroidal Melanoma at the ASRS 2021 Annual Meeting
Press Release. CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Aura Biosciences, a clinical-stage oncology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced the presentation…
Read More
Aura Biosciences Expands Executive Leadership Team and Board of Directors
Press Release. Chris Primiano, J.D., Appointed as Chief Business Officer Antony Mattessich Appointed to the Board of Directors CAMBRIDGE, MA - September 29,2021 - Aura Biosciences, a clinical-stage oncology…
Read More
Aura Biosciences Assembles New Bladder Cancer Focused Scientific Advisory Board
Press Release. Prominent, Multi-Disciplinary Clinicians and Scientists Bring Extensive Strategic Expertise in Urologic Oncology Across All Stages of Research and Development CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Aura Biosciences, a clinical-stage oncology…
Read More
Aura Biosciences Appoints Sapna Srivastava, Ph.D., to its Board of Directors
Press Release. June 08, 2021 07:00 AM Eastern Daylight Time CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aura Biosciences, a clinical-stage oncology company developing a novel class of virus-like drug conjugate (VDC) therapies for…
Read More
Aura Biosciences Announces Publication of Data in Cancer Immunology Research Supporting the Immune Mediated Mechanism of Action of the Virus-Like Drug Conjugate (VDC) Technology Platform with Broad Application in Cancer Treatment
Press Release. Results Support VDCs induction of Pro Immunogenic Cell Death and the Generation of Long Lasting Adaptive Anti-Tumor Immunity - Combination of VDCs with Checkpoint Inhibitors Achieves a…
Read More
Aura Biosciences Expands Executive Leadership Team with the Appointment of Mark De Rosch, Ph.D., as Chief Operating Officer
Press Release. March 24, 2021 CAMBRIDGE, MA – March 24, 2021 – Aura Biosciences, a clinical-stage oncology company developing a novel class of virus-like drug conjugate (VDC) therapies for…
Read More
Aura Biosciences Announces Oversubscribed $80 Million Financing
Press Release. Proceeds to Support Pivotal Program of AU-011 for the First Line Treatment of Choroidal Melanoma and Expansion of Virus-like Drug Conjugate (VDC) Platform in additional Ocular Oncology…
Read More
Aura Biosciences Appoints David Johnson to Its Board of Directors
Press Release. CAMBRIDGE, MA –January 5th, 2021– Aura Biosciences, a clinical-stage oncology company developing a novel class of drug conjugate therapies for multiple oncology indications, today announced the appointment…
Read More
Aura Biosciences Completes $40 Million Series D Financing
Press Release. CAMBRIDGE, MA – April 2, 2019 – Aura Biosciences, a leader in the development of novel targeted therapies in ocular oncology, today announced that it closed a…
Read More
Aura Biosciences Completes $30 Million Series C Financing
Press Release. December 21, 2017 Lead candidate, light-activated AU-011, currently being investigated in Phase 1b/2 study to treat ocular melanoma, an orphan indication Funding to support ongoing clinical development,…
Read More
